Skip to main content
. 2016 Aug 11;11(8):e0160993. doi: 10.1371/journal.pone.0160993

Fig 2. Linagliptin inhibits α-smooth muscle actin (α-SMA) and fibroblast-specific protein-1 (FSP-1) expression in mice with peritoneal fibrosis.

Fig 2

Immunohistochemical analyses of (a) α-SMA and (b) FSP-1 expression in peritoneal tissues on day 21 (original magnification: ×200) in control mice, MGO-injected mice treated with saline, and MGO-injected mice treated with linagliptin. (c, d) Accumulation of α-SMA+ and FSP-1+ cells was observed on day 21 in MGO-injected mice treated with saline, whereas the numbers of α-SMA-and FSP-1-expressing cells were significantly lower in MGO-injected mice treated with linagliptin. Statistical analyses were performed using ANOVA followed by Tukey’s post-hoc test. *P < 0.05.